Key information

🔎 Fund Overview

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead clinical candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM potency. ACR-368 is in Phase II trial across multiple solid tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy, which improves the clinical overall response rate (ORR), and has the potential to enable expedited drug development. The Company is also developing two preclinical drug programs, such as WEE1 inhibitors and PKMYT1 inhibitor.